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Abstract 
Prostate cancer often develops anti‐androgen resistance, possibly via androgen receptor (AR) 
mutations which change antagonists to agonists. Novel therapies with increased anticancer activity, 
whilst overcoming current drug resistance are urgently needed. Enobosarm has anabolic effects on 
muscle and bone whilst having no effect on the prostate. Here we describe the activity of novel 
chemically modified enobosarm analogues. The rational addition of bis‐trifluoromethyl groups into 
ring B of enobosarm, profoundly modified their activity, pharmacokinetic and tissue distribution 
profiles. These chemical structural modifications resulted in an improved AR binding affinity ‐ by 
increasing the molecular occupational volume near helix 12 of AR. In vitro, the analogues SK33 and 
SK51 showed very potent antiandrogenic activity, monitored using LNCaP/AR‐Luciferase cells where 
growth, PSA and luciferase activity were used as AR activity measurements. These compounds were 
10-fold more potent than bicalutamide and 100-fold more potent than enobosarm within the LNCaP
model. These compounds were also active in LNCaP/BicR cells with acquired bicalutamide 
resistance. In vivo, using the AR‐Luc reporter mice, these drugs showed potent AR inhibitory activity 
in the prostate and other AR‐expressing tissues e.g. testes, seminal vesicles and brain. These 
compounds do not inhibit AR activity in the skeletal muscle, and spleen ‐ thus indicating a selective 
tissue inhibitory profile. These compounds were also active in vivo in the Pb-PTen deletion model. 
SK33 and SK51 have significantly different and enhanced activity profiles compared to enobosarm, 
and are ideal candidates for further development for prostate cancer therapy with potentially fewer 
side effects.  
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Introduction
Prostate cancer (PCa) is the most commonly diagnosed male cancer in the Western world (1). Tumor 
growth is initially androgen dependent - driven by the androgen receptor (AR). Androgen receptor 
(AR) signalling pathway remains a key driver of PCa, implicated throughout the different stages of 
the disease, and as such represents an obvious therapeutic target in PCa therapy (2, 3). Androgen 
receptor (AR) is a member of the family of steroid hormone receptors, which are ligand-dependent 
transcriptional regulators for diverse sets of genes involved in both reproductive and anabolic 
actions (4-6). The prototypical model for AR involves ligand binding that induces conformational 
changes in the ligand-binding domain (LBD), revealing a co-activator dimerization surface composed 
of helices 3, 5, and 12, as the LBD site is adjacent to helix 12 (H12). 
Currently, the mainstays of prostate cancer treatment are androgen ablation (to castrate levels) 
and/or antiandrogen treatment, which block AR signalling (2, 3). The major anti-androgens in clinical 
use are bicalutamide and enzalutamide (and historically flutamide, hydroxyflutamide and 
nilutamide) (Figure 1A). However, these compounds bind to AR with low affinity and can induce 
escape mechanisms. Furthermore, under AR amplification or mutation conditions some of these 
compounds exhibit agonist activity and fail to inhibit AR. This resistance may arise from, among 
other mechanisms, mutations to several key residues in the ligand-binding domain (AR-LBD) (7, 8). 
Common mutations in AR found in PCa patients include T877A, W741L, and W741C. Bicalutamide 
(Figure 1A) can act as an agonist in ARW741L and ARW741C while hydroxyflutamide is an agonist in 
ART877A (7, 8). Gain of function mutations are common in prostate cancers and are correlated with 
disease progression, the lack of therapeutic response and poor clinical outcomes. Additionally, AR 
mutations may be selected for during anti-androgen therapy – reviewed in (9, 10) .
Additionally, the use of anti-androgens in patients may elicit moderate side effects e.g. muscle 
wastage, bone density loss and CNS dysfunction – which are exacerbated in elderly men. Therefore, 
there is a growing need for selective androgen receptor modulators (SARM) that would demonstrate 
tissue-selective activity – being inhibitors of the AR in the prostate with tissue sparing effects 
elsewhere (11).
Enobosarm (also referred to as OstarineTM, GTx-024 or S-22) is a non-steroidal selective androgen 
receptor modulator (SARM) with a favourable safety and pharmacokinetic profile (Figure 1B). It 
belongs to the class of arylpropionamides, which are structurally derived from the antiandrogen 
bicalutamide. Enobosarm binds to and activates the AR with enantioselective affinity, potency and 
efficacy similar to, but somewhat less than, that of DHT (12). Transient transfection studies indicate 
that enobosarm is remarkably selective for the AR and it does not cross-react with other nuclear 
hormone receptors. This receptor specificity differentiates enobosarm’s pharmacology from other 
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steroidal androgens and has likely contributed to observations that the drug has generally been well 
tolerated in clinical trials. It has selective anabolic effects and is under clinical development for 
prevention and treatment of muscle wasting (cachexia) in cancer patients (13, 14). 
5 
Results 
Rational design of novel Enobosarm analogues 
Nonsteroidal anti-androgens such as bicalutamide act as AR antagonists (Figure 1A), thus preventing 
androgen-dependent cell growth. In contrast, AR agonists e.g. enobosarm (Figure 1B) may act as 
agonists in all the AR LBD mutants, since they will fit sterically better with the bulk-reducing AR 
mutations than in ARwt (15). The difference in activity between agonists such as enobosarm and 
antagonists such as bicalutamide in ARwt may arise from the linker oxygen’s smaller size relative to 
the sulfonyl group of bicalutamide (Figure 1A&B). This bulk in AR antagonist structure, though small, 
is thought to push the AR helix 12 away from the binding pocket, disturbing the agonist 
conformation of the androgen receptor (16). The current theoretical key to antagonism states that 
the differences observed among AR modulators (agonist or antagonist) are not because of their B-
ring size or shape but because of their linker size and orientation (17). The improved understanding 
is being applied to rationally designed treatment options with novel mechanisms of action. It is 
proposed that AR antagonists should have appending molecular extensions to the core structure of 
AR agonists that interfere with the placement of H12, thereby disrupting co-activator recruitment 
(16, 18, 19). 
In the enobosarm/ARwt co-crystal structure (PDB code; 3RLJ)(17) (Figure 2A&B), the 4-cyanophenyl 
ether group of enobosarm is situated between residues of H12 and the indolyl side chain of Trp741, 
suggesting that in the wild-type receptor (and probably the W741L mutant) the larger substitution 
with the same orientation of the linker would result in a better AR antagonist by pushing against 
Helix 12. We tested this hypothesis in silico by investigating whether the introduction of 3,5-Bis-
trifluoromethyl (3,5-Bis-CF3) into B ring of enobosarm would provide the geometric bulk needed to 
keep ring B towards Helix 12 of AR. Preliminary molecular modelling studies showed that the bis-
trifluoromethyl phenyl moiety (ring B in SK33 and SK51) has significantly changed the orientation of 
ring B so that the (3,5-Bis-CF3) groups are pointing outwards away from Trp741 and towards helix 12, 
thus preventing AR from adapting the AR agonist conformation, whilst keeping the small size of the 
oxygen linker. The combination of the small oxygen linker and the steric hindrance of the (3,5-Bis-
CF3) substitution on ring B resulted in the optimum size and orientation of ring B to impose 
conformational restriction away from Trp741 and towards helix 12 (Figure 2C & D). A small library of 
AR antagonists having the (3,5-Bis-CF3) motif was prepared (20) among which SK33 showed the best 
antiproliferative and metabolic profiles, hence it was selected for further studies.
The introduction of fluorinated substituents into drug candidates can impart a unique set of 
properties owing to the unique combination of electronegativity, size and lipophilicity features of 
fluorinated groups (21-25). These factors can have a substantial impact on the molecular 
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conformation, which in turn affect the binding affinity to the target protein (26, 27). 
Chemical synthesis of SK33 and SK51 
Racemic enobosarm derivatives (SK33 and SK51) were prepared by reacting methacryloyl chloride 
(2) with the corresponding substituted anilines 1a and 1b in dimethylacetamide (DMA) solvent to
obtain phenylacrylamides 3a and 4b which were converted into the corresponding epoxides 4a and 
4b in the presence of a large excess of hydrogen peroxide and trifluoroacetic anhydride in 
dichloromethane (DCM). Opening of the epoxide rings of 4a and 4b with substituted 3,5-bis 
(trifluoromethyl)phenol (5) in tetrahydrofuran (THF) gave the final compounds SK33 and SK51. The 
structures of the synthesised compounds were confirmed using analytical and spectroscopic data (1H 
NMR, 13C NMR, 19F NMR and mass spectrometry), which were in full accordance with their depicted 
structures. SK33 and SK51 were purified (>95% as confirmed by HPLC) and tested as racemic mixture 
(Figure 1C). 
Cellular activity of enobosarm and the trifluoromethylated analogues SK33 and SK51 
The antiproliferative and selective activities of these compounds were tested in vitro in a 
panel of prostate cancer cell lines, namely LNCaP, VCaP, PC3 and Du145. LNCaP and VCaP 
represent prostate cells which have retained the expression of the androgen receptor (28, 
29). However, LNCaP cells overexpress a mutant AR, with a T877A mutation in the ligand 
binding site. The VCaP cell line overexpresses wild type AR. Both cell lines are responsive to 
androgens and cells will express androgen responsive genes. The PC3 and Du145 cells do 
not express the AR nor do they express androgen responsive genes.  
Cells were exposed to increasing concentrations of anti-androgens for 96 hours and cell 
viability was analysed using the MTT assay. In LNCaPAR+ve cells the parental compound 
enobosarm, showed insignificant activity with the IC50 = 40 M, however, the 
trifluoromethylated enobosarm analogue, SK33, demonstrated a significantly potent activity 
with IC50 = 0.2 M (Figure 3A). Moreover, when compared to the antiandrogen 
bicalutamide, the novel compounds showed an increased efficacy (Figure 3B). SK51 also 
displayed an increased activity compared to bicalutamide (IC50 = 0.7M) (Figure 3B). 
In PC3AR-ve cells, enobosarm showed activity only at relatively high dose (Figure 3C), whilst 
SK33 showed some moderate activity. When compared to bicalutamide, SK33 showed a 
significantly increased increased activity. On the other hand, the anti-proliferative activity of 
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SK33 in LNCaPAR+ve cells was over ten times higher than that of its activity against PC3AR-ve
cell line (Figure 3D). 
Furthermore, the panel of prostate cancer cell lines were screened for their expression of 
the target androgen receptor (AR) by qPCR. As expected, LNCaPAR+ve and VCaPAR+ve cells 
showed robust expression of AR whilst AR was not detectable in PC3AR-ve and Du145AR-ve cells 
(Figure 3E).  
Figure 3F depicts the summary of the activity profile of the SK33 and SK51 compounds in 
the four PCa cell lines where a clear activity difference (selectivity) can be observed 
between the AR+ve cell lines (LNCaP and VCaP) and the AR-ve cell lines (PC3 and Du145). 
SK33 decreases cells entering S-phase in LNCaP cells but not in PC3 cells 
To further analyse the activity of these compounds in prostate cancer cell lines we 
treated LNCaP (AR+ve) or PC3 (AR-ve) cells with 10M of antiandrogen (or vehicle 
DMSO) for 48 hours. These cell lines were collected for FACS analysis and standard cell 
cycle profiling using propidium iodide staining for DNA content, was carried out.  
LNCaP cells showed a decrease in the number of cells in S phase with all the anti-androgen 
compounds. SK33 showed the highest reduction of the number of cells in S phase, 
followed by SK51, enzalutamide and then bicalutamide, respectively. (Figure 3G). No 
apparent cell toxicity could be visualised as estimated by the absence of a sub-G1 
population or fragmented necrotic cells (Figure 3G). In the PC3 cell line, no significant 
effect was observed with any of the tested compound (Figure 3H). However, a small 
increase in G2/M phase could be detected with SK33 in PC3 cells.    
SK33 reduces AR transcriptional activity 
We then analysed the ability of SK33 to inhibit the activity of the AR protein i.e. the ligand 
activated transcription factor activity. The LNCaP/Luc cell line, has an integrated luciferase 
reporter gene under the specific control of the AR transcription factor, as shown in the 
schematic figure 4A (30). Growing these LNCaP/Luc cells in charcoal stripped serum for 
72hours removes exogenous androgens and reduced the expression of AR-responsive genes 
down to a baseline level, as monitored by qPCR. Adding a synthetic androgen (R1881) back 
into the media (0-10nM) increased both PSA and Luciferase gene expression in a dose 
dependent manner (Figure 4B). Androgen treatment does not affect G418 gene expression 
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(coexpressed from the same integrated plasmid as the luciferase reporter) nor did it affect 
the expression of housekeeping genes L19, -actin and GAPDH. The ability of the anti-
androgens to block this androgen-dependent gene upregulation was then further tested. 
Treating hormonally starved LNCaP cells with R1881 showed a 9-fold upregulation of the 
endogenous gene PSA. When treated with increasing doses of either bicalutamide or SK33 a 
dose dependent inhibition of gene expression was seen. SK33 showed a greater PSA 
inhibition than bicalutamide at 1 and 10M (Figure 4C). Conversely, the parental compound, 
enobosarm, showed a mild stimulatory activity (Figure 4D).  
We then examined the real-time activity of AR in live LNCaP/Luc cells in response to 
increasing doses of SK33 compared to the parental compound enobosarm and the anti-
androgen bicalutamide. Live imaging and photon flux measurements of LNCaP/Luc cells 
grown on 96 well plates in the presence of 0-100M compound for 24 hours resulted in a 
strong inhibition of AR-mediated luciferase activity (Figure 4E). The AR inhibitory 
concentration [50%] for both SK33 and bicalutamide were approx. 1M. Bicalutamide 
showed no further inhibitory effects past this concentration. However, SK33 maintained a 
dose dependent inhibition, completely inhibiting the AR-mediated luciferase activity at 
50-100M concentration (Figure 4F). 
SK33 and SK51 are active in LNCaP cells with acquired bicalutamide resistance. 
LNCaP cells were grown in increasing concentrations of bicalutamide for 3-6 months, until 
proliferation was seen. This bicalutamide resistant cell line (LNCaP/BicR) then grew well in 
20M bicalutamide, with cell cycle kinetics similar to that of the parental cell line. An 
increased expression level of AR was seen in this cell line upon qPCR analysis (Figure 5A). 
Treating this cell line with increasing doses of bicalutamide showed a proliferative response 
– at 20-25M, whereas the parental cell line showed sensitivity and an IC50 of 3M (Figure
5B). The LNCaP/BicR cell line also showed a partial cross-resistance to enzalutamide (IC50 = 
5M approx.), Figure 5C. We then analysed if the mechanism of the acquired resistance to 
bicalutamide extended to the novel agents SK33 and SK51. Treatment of LNCaP/BicR cells 
with increasing concentrations of SK33 and SK51 for 96hours resulted in a dose-dependent 
response and an inhibition of cell growth, rather than being proliferative agents as 
bicalutamide (Figure 5D), with IC50 of approximately 2M for SK51 and 5M for SK33. 
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Although not as active as in the parental sensitive cell line, SK51 did show an improved 
activity over enzalutamide (& bicalutamide). 
In vitro aqueous solubility and microsomal metabolic stability 
Subsequently, an early in vitro pharmacokinetic study of the most promising compound, 
SK33, was performed. The metabolic stability of SK33 was tested in human liver 
microsomes, where compounds were incubated for 45 min with pooled liver microsomes 
and the intrinsic clearance (CLint) and half-life (t1/2) values were calculated based on 5 time 
points.  Compound SK33 is characterised by an increased metabolic stability in comparison 
with the standard – bicalutamide (see Table 1). SK33 has microsomal half-life (t1/2) of 32 hr, 
which compares to that of standard drugs (bicalutamide and enzalutamide) and represents 
a good starting point for optimisation towards a weekly or twice-weekly administrable 
product. No observed in vitro cardiotoxicity was observed in our preliminary studies (7.6 % 
inhibition of hERG at 25M concentration) (http://cyprotex.com). Because of these 
promising in vitro properties and the potent anti-proliferative profile in prostate-cancer 
cell lines, SK33 was selected for more detailed pre-clinical in vitro and in vivo studies. 
SK33 is a potent inhibitor of AR in the ARE-Luc reporter mouse – and shows tissue 
specificity 
The transgenic ARE-Luc mouse model shows AR-driven luciferase activity in all tissues in 
response to androgen action and activity can be monitored in live animals in real time 
(31). Using age-matched male mice (littermates) we analysed the basal AR-driven 
luciferase levels in mice prior to treatment. ARE-Luc mice were injected with D-luciferin 
and imaged using an IVIS CCD camera in order to obtain baseline visualisation and 
measurements of androgen receptor tissue activity. ARE-Luc mice were then injected 
sub-cutaneously with 50mg/kg bicalutamide, SK33 or vehicle (DMSO) control and left for 
24 hours (n=3 for each treatment), after which the mice were imaged again under the 
exact same conditions. Post treatment mice were imaged again for luciferase activity 
(Figure 6A). Luciferase activity was measured from three regions of interest (ROI), 
including the head, abdominal and gonadal region (Figure 6B). Bicalutamide and SK33
treatment resulted in a decreased luciferase activity in all areas. However, mice 
treated with SK33 showed a greater reduction of 
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luciferase activity in these areas when compared to bicalutamide. DMSO vehicle did not 
significantly affect luciferase activity in any region (Figure 6C). 
Tissues were then removed from sacrificed animals, and RNA was extracted and analysed by 
q-PCR for luciferase transcripts in each individual tissue. Bicalutamide and SK33 showed
strong reduction in luciferase transcripts compared to vehicle or untreated mouse tissues. 
Although similar, SK33 reduced luciferase transcripts to a greater extent than bicalutamide 
– with significantly greater effects in the brain. Neither bicalutamide nor SK33 had
significant effects on AR activity in the spleen. However, SK33 did not reduce luciferase 
activity in the leg muscle and showed a significant upregulation of luciferase transcripts in 
this tissue (Figure 6D). Additionally, both bicalutamide and SK33 have reduced luciferase 
enzymatic activity in the prostate, testes and brain. Both anti-androgens showed significant 
inhibition compared to vehicle control. Although slightly more inhibition was seen in the 
SK33 treated mice, the antiandrogens did not show statistically significant differences from 
each other  (Figure 6E).  
SK33 is a potent inhibitor of AR in the PTenko mouse model for prostate intraepithelial 
neoplasia (PIN). 
PTen loss is one of the most frequent events in prostate cancer both at the initiation stage 
and during late stage metastatic development - found in 30%+ of all human primary 
prostate cancers, and 60%+ of higher grade metastatic lesions. Wang et al, established 
Ptenloxp/loxp;Pb-Cre4 mice, which have conditional Pten alleles deleted by a Probasin (Pb) 
promoter-driven Cre recombinase, limiting Pten deletion to the prostatic epithelial layer 
(32). The mouse model of prostate-specific probasin-mediated Pten deletion leads to 
prostate intraepithelial neoplasia (PIN) leading to adenocarcinoma thereafter. Although the 
mouse prostate structure is different to human, there are several points of commonality –
specifically with the glandular epithelial AR-driven structure. 
Ptenloxp/loxp;Pb-Cre4 mice with an integrated androgen reporter were injected sub-
cutaneously with 50mg/kg bicalutamide, SK33 or vehicle (DMSO) control and left for 
24hours (n=3 for each treatment). Prostate tissues were collected for qPCR and luciferase 
assay analysis. Upon q-PCR for luciferase transcripts both anti-androgens showed significant 
inhibition compared to vehicle control with more inhibition in the SK33 treated mice than 
bicalutamide, but the anti-androgens did not show statistically significant difference from 
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each other (Figure 6F). 
In AR+ve mouse Ptenko cells growing in culture (PTEN-CaP8 -ATCC CRL-3033), SK33 showed a 
stronger activity than enzalutamide or bicalutamide (Figure 6G).  
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Discussion 
Prostate cancer (PCa), like the prostate gland from which it is derived, is androgen 
dependent – at least in the initial stages. The inhibition of the androgen receptor activity 
either by anti-androgen therapy or by androgen ablation remains the mainstay of treatment 
choices. Recently, there has been a movement away from classical anti-androgens due in 
part to the development of resistance to these compounds and the advantages of more 
novel agents e.g. the anti-testosterone synthesis agent abiraterone. Resistance has 
been historically linked to the development of AR mutations especially in the ligand 
binding site. For example, AR T887A, W741L and W741C have been found to arise in 
patients relapsing under flutamide or bicalutamide therapy (7, 8). 
However, even in apparent castrate resistant prostate cancer the AR may still be a key 
molecule to cell growth, and as such remains a viable target for therapeutic intervention. 
The current clinically used AR antagonists bind the receptor ligand binding site, but with far 
less efficiency and affinity than natural agonists. The mechanism of the difference 
between the structure of AR antagonists and partial AR agonists, such as enobosarm, 
has been associated with the sulfonyl group on the antagonist being larger than the 
oxygen linker group of the agonist, thus causing a better steric fit. The larger size of the 
antagonist then pushes away helix 12, inhibiting the folding of the activated AR. 
Here we describe the chemical modification of an AR partial agonist – enobosarm. 
Enobosarm has been shown to have anabolic activity in the body e.g. on bone and muscle 
mass, but to have minimal effects on the gonadal tissues i.e. an agent with selective 
AR modulating effects (SARM). The introduction of the 3,5-Bis-trifluoromethyl groups 
was theorized to give bulkier sides to the B ring thus inhibiting helix 12 folding. In 
essence changing a high affinity agonist to a high affinity antagonist. Two bis-
trifluoromethyl-containing enobosarm analogs named SK33 and SK51 were the focus of this 
study. 
Initial screening in prostate cancer cell lines indicated that the parental compound, 
enobosarm, was inactive in all of them, whereas the SK33 and SK51, modified enobosarm 
analogues showed higher activity (200 fold) in AR+ve cell lines and modest or low activity in 
AR-ve cell lines. SK33 showed the highest activity, being more active than the current 
clinically used anti-androgen – bicalutamide. Treating LNCaP cells with SK33, resulted in the 
inhibition of cell cycle progression, with cells arresting in G1. No apoptotic response or 
cellular fragmentation was observed. AR inhibition has been associated with the inability of 
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cells to enter the cell cycle, as the AR may act as a replication licensing protein in prostate 
cells (33, 34). 
The LNCaP cell line is an androgen sensitive cell line with a T877A mutation in the LBD of the 
AR. Treating this cell line in culture for an extensive period with bicalutamide gave rise to a 
resistant subclone (LNCaP/BicR) which proliferated in the presence of high doses of 
bicalutamide, and showed an enhanced expression of AR. This switch to AR agonism is 
indicative of clinical prostate cancer as it progresses, and this work has been 
previously reviewed (35, 36). We did not detect other LBD mutations in this cell line. 
Although not as active as in the parental cell line SK33 and especially SK51 showed 
moderate activity. At this stage it is unclear if the concentration of SK33 (&SK51) 
required to inhibit the acquired resistance phenotype may be achievable in vivo, but 
their increased metabolic stability, resistance to oxidative metabolism and detoxification 
together with increased solubility may translate to high levels of drug in circulation. 
Additionally and of clinical importance, SK51 showed increased activity over enzalutamide 
in the LNCaP/BicR cells.  
It is rare that an inhibitor compound such as an anti-androgen can be tested in a biological 
system where there is a highly specific real-time reporter for its target protein activity - 
integrated into the host genome. Utilizing an LNCaP cell line with an integrated AR-driven 
luciferase reporter (30) we analyzed the effect of these compounds directly on the 
transactivation function of the AR. SK33 resulted in a stronger inhibition of AR-mediated 
gene activation of both the endogenous gene PSA and the transgene luciferase, than that 
mediated by bicalutamide. SK33 could also competitively inhibit the AR in the presence of a 
strong synthetic androgen (R1881), whilst enobosarm itself had a mildly stimulating effect. 
Further testing in vivo using unique AR-reporter mice, developed by the authors (31), 
showed the anti-androgen activity of these compounds in the target tissue i.e. prostate, as 
well as in peripheral tissues, in real time within the same animal. Here, side effects, and 
bystander effects could be monitored. SK33 showed a stronger or equal anti-androgen 
effect in most tissues, when compared to bicalutamide at the same dosage concentration. 
But, interestingly we observed that the effects of SK33 upon leg muscle AR activity was 
stimulatory, and the effects in the spleen were minimal.  
The anabolic effects of enobosarm have been well documented, although its mechanism of 
action in specifically stimulating skeletal muscle AR and not prostate or gonadal AR remains 
elusive. Since SK33 is a modified analog of enobosarm the effects on skeletal muscle was 
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interesting to observe, especially given its simultaneous high inhibitory activity in the 
prostate and other tissues. The rational addition of bis-trifluoromethyl groups into ring B of 
enobosarm seems to have successfully exaggerated the SARM activity of enobosarm. The 
mechanism of SARM-like compounds remain relatively unknown but locally expressed AR 
tissue-specific cofactors have been postulated to govern the activity of AR modulating 
compounds such as SARMs. Although our results are limited to the mouse leg skeletal 
muscle, the use of such a compound in prostate cancer patients may ease side effects such 
as muscle wastage and fatigue, whilst maintaining prostate AR inhibition. The effects 
on other muscle tissues e.g. the AR-responsive levator ani muscle, in the mouse 
was unavailable.  
It should also be noted that SK33 showed very potent inhibitory effects in the brain - this 
may reflect the increased lipophilicity of the fluorinated compounds in traversing the blood-
brain barrier or in fact their increased anti-androgen potential. The CNS-specific effects 
could not be determined in the mouse model, but no deleterious effects on motor function 
or behavior was observed. The effects in humans could well correlate with CNS-related side 
effects. 
Finally, within a developing hyperplasia / adenocarcinoma in situ in mice with homozygous 
PTEN deletion we observed that SK33 was equal to or better than bicalutamide in 
reducing AR activity.  
Conclusions 
We demonstrate that structure-based design can efficiently engineer second-generation AR 
antagonists that have clinical potential to circumvent anti-androgen resistance by complementing 
receptor mutations at the molecular level. In principle, there is a limited number of mutations that 
can cause an AR antagonist to function as an AR agonist, therefore, it is conceivable that such 
approaches may ultimately lead to the development of anti-androgens that resist mutations that 
cause anti-androgen withdrawal syndrome.  
Utilising novel in vitro and in vivo screening techniques and models, ideally suited to analyze and 
evaluate novel antiandrogens, we have identified a novel anti-androgen candidate SK33. This bis-
trifluoromethyl-containing enobosarm analog, displays better activity than bicalutamide in vitro with 
increased efficacy against acquired anti-androgen resistance. Importantly, SK33 has comparable 
activity in vivo, but maintains a degree of tissue selectivity associated with its SARM – enobosarm 
parental molecule. The increased stability and potential differential side effect profile of these 
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molecules may make them useful drugs for prostate cancer treatment. 
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→ 100% eluent B in eluent A.
General method for the preparation of intermediates (3a,b) 
Methacryloyl chloride 2 (2.63 mL, 27.16 mmol) was added over the course of 10 minutes to a stirring solution 
of the different aniline 1a, b (3.4 mmol) in N,N-dimethylacetamide (10 mL) at r.t. for 3 h. After the reaction 
was complete, the mixture was diluted with ethyl acetate (100 mL), extracted with sat. aq. NaHCO3 solution 
(3x25 mL) and with cold brine (4x50 mL). The organic layer was dried over Na2SO4 and the solvent was 
removed at reduced pressure. The crude residue was purified by flash column chromatography. 
General method for the preparation of intermediates (4a,b) 
To a stirred solution of the intermediates (3a,b) (3 mmol) in DCM (7 mL) was added 30% hydrogen peroxide 
(3.6 mL, 32.03 mmol). The reaction mixture was put in a water bath at r.t. and trifluoroacetic anhydride (3.7 
mL, 26.7 mmol) was added slowly to the mixture, which was then stirred for 24 h. The reaction mixture was 
transferred to a separating funnel using DCM (30 mL). The organic layer was washed with distilled water (20 
mL), sat. aq. Na2S2O3 (4x20 mL), sat. aq. NaHCO3 (3x20 mL) and brine (20 mL), dried over Na2SO4 and 
concentrated at reduced pressure. 
General method for the preparation of compounds SK33 and SK51 
To a mixture of NaH (60% in mineral oil, 0.050 g, 1.23 mmol) in anhydrous THF (2 mL) at 0 °C under Ar 
atmosphere was added a solution of the 3,5-bis-trifluoromethylphenol 5 (1.11 mmol) in 1 mL of anhydrous 
Materials and Methods 
All chemicals were purchased from Sigma Aldrich (Gillingham, United Kingdom) or Alfa Aesar 
(Heysham, United Kingdom) and were used without further purification. All reactions were 
performed under a nitrogen atmosphere. H- NMR (500 MHz), C- NMR (125 MHz) and F-NMR (470 
MHz) spectra were recorded on a Bruker Avance 500 MHz spectrometer at 25 C. Chemical shifts (δ) 
are expressed in parts per million (ppm) and coupling constants (J) are given in hertz. The following 
abbreviations are used in the assignment of NMR signals: s (singlet), bs (broad singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt (doublet of triplet), td (triple doublet), 
m (multiplet). Mass spectrometry was run on a Bruker Micromass system in electrospray ionization 
mode. Thin Layer Chromatography (TLC): precoated aluminium backed plates (60 F254, 0.2 mm 
thickness, Merck) were visualized under both short and long wave UV light (254 and 366 nm). Flash 
column chromatography was carried out using silica gel supplied by Fisher (60 A, 35-70 µm). Purity 
of prepared compounds was determined by Analytical High-Performance Liquid Chromatography 
(HPLC) analysis using either a ThermoScientific or a Varian Prostar system. All compounds tested in 
biological assays were > 95% pure. HPLC using the eluents water (eluent A) and acetonitrile (eluent 
B). Column; Varian Pursuit, 150 mm × 4.6 mm, 5.0 μm. Flow rate;  1.0 mL/min, gradient 30 min 10% 
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1H NMR (CDCl3-d1) δ 9.20 (bs, 1H, NH), 8.16 (d, J = 2 Hz, 1H, ArH), 8.00 (dd, J = 2, 8.5 Hz, 1H, ArH), 7.82 (d, J = 
8.5 Hz, 1H, ArH),  7.53 (s, 1H, ArH), 7.36 (s, 2H, ArH),  4.59 (d, J= 9 Hz, 1H, CH2), 4.13 (d, J = 9 Hz, 1H, CH2), 3.49 
(bs, 1H, OH), 1.67 (s, 3H, CH3); 19F NMR (CDCl3-d1) δ -62.24, -63.09; 13C NMR (CDCl3-d1) δ 172.03 (C=O), 158.28
(ArC), 141.29 (ArC) , 135.92 (ArCH), 134.18 (q, 2JC-F = 32.6 Hz, ArC), 133.16 (q, 2JC-F = 33.3 Hz, ArC), 122.94 (q, 1JC-
F = 264.5 Hz, CF3), 122.05 (q, 1JC-F = 272.6 Hz, CF3), 121.84 (ArCH),  117.33 (q, 3JC-F = 5.1 Hz, ArCH), 115.56 (q, 3JC-F
= 3.6 Hz, ArCH), 115.38 (ArC), 115.14 (q, 3JC-F = 3.8 Hz, ArCH), 104.92 (ArC), 75.83 (COH), 73.10 (CH2), 23.04
(CH3). MS [ESI, m/z]: 501.1 [M+H], 523.1 [M+Na].  HPLC: retention time = 25.18 min. 
3-(3,5-bis(trifluoromethyl)phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl) propanamide 
(SK51) 
Purified by flash column chromatography eluting with n-hexane/EtOAc 100:0 v/v increasing to n-hexane/EtOAc 
90:10 v/v. Obtained in 78 % yield as a white solid. 
1H NMR (CDCl3-d1) δ 9.68 (bs, 1H, NH), 8.76 (d, J = 9 Hz, 1H, ArH), 8.59 (d, J = 3 Hz, 1H, ArH), 8.47 (dd, J = 2.5, 
9.5 Hz, 1H, ArH), 7.56 (s, 1H, ArH), 7.36 (s, 2H, ArH), 4.59 (d, J= 9 Hz, 1H, CH2), 4.15 (d, J = 9 Hz, 1H, CH2), 3.25 
(bs, 1H, OH), 1.69 (s, 3H, CH3); 13F NMR (CDCl3-d1) δ -61.59, -63.06; 13C NMR (CDCl3-d1) δ 172.02 (C=O), 158.15
(ArC), 143.17 (ArC), 140.38 (ArC), 133.16 (q, 2JC-F = 33.8 Hz, ArC), 133.03 (q, 2JC-F = 32.8 Hz, ArC), 128.38 (ArCH),
123.22 (q, 1JC-F = 268.3 Hz, CF3), 122.75 (q, 1JC-F = 271.3 Hz, CF3),122.62 (ArCH), 122.46 (q, 3JC-F = 6.3 Hz, ArCH),
115.67 (q, 3JC-F = 3.8 Hz, ArCH), 115.11 (ArCH), 75.86 (COH), 73.93 (CH2),  22.94 (CH3). MS [ESI, m/z]: 521.1
[M+H], 543.1 [M+Na].  HPLC: retention time = 26.42 min. 
Cell culture 
All cell lines were purchased LGC Standards (Teddington, UK) and used within 6 passages, and 
subjected to regular mycoplasma screening (Geneflow PCR test, Lichfield, UK). LNCaP cells were 
maintained at 37oC, 5% CO2 in RPMI medium with 10% foetal bovine serum (First Link Ltd, Brierley 
Hill, U.K.).  PC3, VCaP and Du145 and mouse Pten null cells were maintained in DMEM medium 
(Sigma) with 10% foetal bovine serum (First Link UK,). All media was supplemented with 2mM L-
glutamine, 100units/ml penicillin, 100mg/ml streptomycin (Sigma). For hormone depletion 
experiments, 72 hours before androgen exposure, medium was replaced with ‘starvation medium’ 
THF. This mixture was stirred at r.t. for 20 min. A solution of the different intermediates (4a,b) (0.74 mmol) in 
anhydrous THF (3 mL) was added slowly. The reaction mixture was stirred at r.t. o.n. The mixture was then 
diluted with ethyl acetate (30 mL), washed with brine (15 mL) and water (30 mL), dried over Na2SO4
and concentrated under vacuum. The crude residue was purified by flash column chromatography. 
3-(3,5-bis(trifluoromethyl)phenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide 
(SK33)
Purified by flash column chromatography eluting with n-hexane/EtOAc 100:0 v/v increasing to n-hexane/
EtOAc 90:10 v/v. Obtained in 85 % yield as a white solid. 
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consisting of phenol red-free RPMI (or DMEM) medium, supplemented with 5% charcoal-stripped 
foetal bovine serum (First Link UK). All cell lines were obtained from the ATCC cell bank. 
MTT Assay 
The MTT assay was used as a cell viability assay for the all the cell lines listed using the anti-androgen 
compounds.  Briefly, cells (5 × 104 cells/ml) were seeded into 96-well plates (200ul/well), allowed to 
attach and grow for 24hr and subsequently treated with varying concentrations of antiandrogens (0–
100 μM) for 96 hours. Optimal seeding densities were premeasured for linear growth over the 
96hours. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5mg/ml in PBS) was 
added to a final concentration of 0.5mg/ml for 4 h at 37oC. After four hours, purple formazan 
crystals, formed by mitochondrial reduction of MTT, were solubilized in acidified isopropanol (200μl/
well) and the absorbance was read at 570 nm after 10 min incubation.  Percent inhibition of viability 
was calculated as a % of untreated control and the cytotoxicity / cell growth inhibition was 
expressed as IC50. 
Luciferase Assays 
Cells were washed and lysed in reporter lysis buffer (Promega). Lysate was mixed with D-luciferin 
substrate (Promega) and light emission measured using the Promega Glomax multi luminometer.  
For live cell imaging D-luciferin substrate was added directly into the cell media and plates were 
imaged on a Syngene G:Box imager.  
Tissue was pulverized by grinding in liquid nitrogen and then completely homogenised, using a 
microfuge pestle, in reporter lysis buffer with protease inhibitors (Promega). Lysate (20µl) was mixed 
with luciferin substrate (20µl) and light emission measured using the Promega Glomax multi 
luminometer. Light emission was then normalised to protein content as measured by a Bradford 
Assay. 
RNA extraction and RT-PCR 
Total RNA samples were prepared using Trizol reagent (Sigma) and converted to cDNA using the 
GoScript™ Reverse Transcription System (Promega). 
Q-PCR
Reactions were performed in triplicate on cDNA samples in 96-well optical plates on an ABI Prism 
StepOne System (ThermoFisher, U.K.). Reactions consisted of 2 μl cDNA, 7 μl PCR-grade water, 10 μl 2× 
TaqMan Universal PCR Master Mix (Applied Biosystems), 1 μl Taqman specific assay probes 
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(Applied Biosystems) for PSA, TMPRSS2, KLK2, and L19. Parameters were: 50°C for 2 min, 95°C for 10 
min, 40 cycles of 95°C for 15 sec and 60°C for 1 min. Data was recorded using Sequence Detector 
Software (SDS version 2.3; PE Applied Biosystems). Levels were normalised to GAPDH, -actin and 
RPL19. 
Animal experiments 
All mouse procedures were performed in accordance with the UK Animals (Scientific Procedures) Act 
1986 under Home Office license. ARE-Luc strains were made and available ‘in house’ (31), and 
Ptenloxp/loxp;Pb-Cre4 were obtained from The Jackson Laboratory. 
Luciferase imaging 
Anaesthetized mice (3% isofluorane with O2 carrier, Abbott Animal Health UK) were injected i.p. or 
s.c. with D-luciferin (Caliper Life Sciences Ltd, Runcorn, UK) at 150 mg/kg, 10 min before imaging.
Light emission from luciferase was detected by the IVIS Imaging System 100 series (Xenogen 
Corporation), and overlaid as a pseudocolour image with reference scale, upon a greyscale optical 
image. 
For ex vivo imaging, mice were sacrificed 10 min after luciferin injection, and immediately dissected. 
Target organs were rinsed briefly in PBS and placed under the bioluminescent camera. Tissues were 
then collected for luciferase assays, RNA extraction or fixed in 10% formaldehyde before wax 
embedding and sectioned using standard procedures. 
Cell cycle analysis (FACS) 
Cells were grown on 10cm dishes for 24-96 h ± treatments. Cells were then trypsinized, washed 
twice in PBS, fixed in 70% ethanol at 4 °C, were stained with 5 g/ml propidium iodide and RNA 
removed using 50 mg/ml RNase A. FACS analysis was carried out using a FACS Calibur (Beckton-
Dickinson, Oxford, UK), using linear scale representation of forward and side scatter during flow 
analysis, as well as DNA content. Single cells were gated and the cell cycle profiles measured using 
FCS Express4 software, using the built in kinetics & cell cycle analysis best-fit model for cell cycle 
phase identification. A total of 10 000 events were measured per sample. 
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Tables: 
Metabolic stability 
(t1/2 mins)
Plasma protein 
binding assay (PPB) 
%
%hERG inhibition at 
25μM
Bicalutamide 214 n.d. 96 *
SK33 1930 94.7 7.64
Table 1. t1/2 calculated in human liver microsomes; SK33 is metabolically stable with no loss 
of parent compound detected for the duration of the assay. Plasma protein binding (PPB) 
assay; results are expressed in terms of mean % bound from duplicate experiments. 
Cardiotoxicity expressed in terms of % hERG inhibition at 25 μM compound concentration.
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Figure legends 
Figure 1. 
A, Chemical structure of the clinically used non-steroidal antiandrogens; flutamide, 
hydroxylflutamide, nilutamide, bicalutamide and enzalutamide showing rings A and B. B, 
Chemical structure of enobosarm (left), SK33 and SK51 (right). C, Chemical synthesis of SK33 
and SK51 compounds, reagents and conditions: i) DMA, rt, 24h, ii) H2O2, DCM, rt, 2h, iii) 
NaH, THF, rt, 24 h. 
Figure 2. 
(A, B) X-ray structure of enobosarm (red-carbons) co-crystallised with (AR wt) in the agonist 
conformation showing the orientation the distal ring B extending away from Helix 12 (H12) 
towards Trp741. (C, D) Overlaid predicted binding modes of SK33-R (pink carbons), SK33-S 
(turquoise carbons) and enobosarm (grey carbons) inside the AR-LBD showing the 
orientation of ring B with the bis-CF3 groups inducing geometric bulk keeping Helix 12 in the 
antagonist conformation (open) even upon the development of adaptive (resistant) bulk 
reducing mutations. 
Figure 3. Enobosarm analogues SK33 and SK51 show potent and selective activity in AR 
positive prostate cancer cells. 
MTT cytotoxicity assays of LNCaP cells treated with increasing doses of enobosarm or SK33 
(A) or Bicalutamide, SK33 and SK51 (B) at 0-100M. MTT cytotoxicity assays of PC3 cells
treated with increasing doses of enobosarm or SK33 (C) or Bicalutamide, SK33 and SK51 (D) 
at 0-100M for 96hr. E, Q-PCR analysis of a panel of prostate cancer cells for AR expression. 
Data represents the mean of three independent experiments. Data was normalised to 
GAPDH, -actin and RPL19 housekeeping genes. F, Bar chart representing a summary of the 
IC50 values for the 4 cell lines listed according to their AR status. G, FACS analysis of LNCaP 
cells treated with 10M bicalutamide, enzalutamide, SK33, SK51 or vehicle control for 
48hours, and analysed for S phase (left hand side). Histograms showing DNA content (PI 
fluorescence) of treated LNCaP cells (right hand side). H, FACS analysis of PC3 cells treated 
with 10M bicalutamide, enzalutamide, SK33, SK51 or vehicle control for 48hours, and 
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analysed for S phase (left hand side). Histograms showing DNA content (PI fluorescence) of 
treated PC3 cells (right hand side). 10,000 gated cells were measured for each experiment. 
Figure 4. SK33 and SK51 inhibit AR-mediated transcriptional activity in prostate cancer 
cells. 
A, Schematic diagram of the activation of the synthetic androgen reporter construct 
integrated into the LNCaP/ARE-Luc cell line. Ligand bound AR activates the expression of the 
luciferase reporter gene which in the presence of luciferin substrate gives off 
bioluminescence directly proportional to AR activity. B, Q-PCR analysis of the endogenous 
androgen induced gene PSA and the transgenes luciferase and G418 (Neomycin resistance 
gene - aminoglycoside 3‘-phosphotransferase) in LNCaP/ARE-Luc cells. Cells were grown for 
72hours in charcoal stripped FCS and then treated with 0-10 nM R1881. Data represents 
the mean of three independent experiments. Data was normalised to GAPDH, -actin 
and RPL19 housekeeping genes. C, Q-PCR analysis of PSA gene expression in LNCaP cells 
grown in charcoal stripped medium for 72hours and then treated with R1881 in the 
presence of increasing concentrations of bicalutamide or SK33 (0-10 M) or 
enobosarm (D). Data represents the mean of three independent experiments. Data was 
normalised to GAPDH, -actin and RPL19 housekeeping genes. E, Grey scale image of 
bioluminescence from live LNCaP/Luc cells treated with enobosarm, SK33 and bicalutamide 
(0-100 M) for 24 hours. F, Line graph indicating bioluminescence activity measurements 
from LNCaP/Luc cells treated with increasing concentrations of bicalutamide, enobosarm 
and SK33 for 24 hours. ** = p>0.01.
Figure 5. SK33 is active in LNCaP cells with acquired bicalutamide resistance. 
A, Bar graph indicating the relative expression levels of AR in LNCaP and LNCaP/BicR cells. 
Data represents the mean of three independent experiments. Data was normalised to 
GAPDH, -actin and RPL19 housekeeping genes. B&C, MTT cytotoxicity assays of LNCaP or 
LNCaP/BicR cells treated with increasing concentrations of bicalutamide (B) or enzalutamide 
26 
(C) for 96 hours. D, MTT cytotoxicity assays of LNCaP/Bic20 cells treated with increasing
concentrations of bicalutamide, SK33 and SK51 for 96 hours. 
Figure 6. SK33 inhibits AR transcriptional activity in vivo and in prostate intraepithelial 
neoplasia (PIN). 
A, Bioluminescent imaging of live ARE-Luc mice pre and post treatment with bicalutamide or 
SK33 (or DMSO vehicle) for 24 hours. Image represents a grey scale image overlaid with 
pseudo-colour bioluminescent activity data (scale represents flux rate of photons/sec/cm2). 
B, grey scale image of an ARE-Luc mouse, white circles represent the three regions of 
interest measurements for each mouse. C, Bar graph representing relative bioluminescent 
data emanating from the three regions of interest - head, abdomen and gonadal regions. 
Data is normalised to mouse bioluminescence pre-treatment with bicalutamide, SK33 (50 
mg/kg) or DMSO vehicle. D, Q-PCR analysis of luciferase expression from various body 
tissues as indicated. Data is presented as luciferase / housekeeping genes (GAPDH, RPL19 
and -actin). E, Bar graph indicating relative luciferase enzymatic activity from various 
tissues from ARE-Luc mice treated with either bicalutamide, SK33 or DMSO. F, Q-PCR 
analysis of luciferase expression from the mouse PTenko prostate tissues. Data is presented 
as luciferase / housekeeping genes (GAPDH, RPL19 and -actin). G, MTT assay of PTen null 
mouse prostate cells treated with increasing doses of bicalutamide, enzalutamide and SK33 
for 96hours.   *= p value 0.05, ** = p value 0.01.  
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